Skip to content
Aarti Drugs logo

Aarti Drugs

AARTIDRUGS NSE
₹455.80 −10.50 (−2.25%)
P/E
21.76
View as Markdown
MCP
Close 4 Nov 2026 ₹455.80 −33.10 −6.77% 1Y
Start ₹488.90

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
12.00%
Debt to Equity
0.37
EPS (TTM)
₹20.95
Book Value
₹169.70
Market Cap
—
P/E (TTM)
21.76
P/B
2.69
ROE
13.40%
Dividend Yield
0.43%
EBITDA
₹312 Cr
52W High
₹534.00
52W Low
₹318.95
Day Range
₹440.20 – ₹496.95
Volume
31,60,142

Peer Comparison

Healthcare › Pharmaceuticals

Aarti Drugs peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Aarti Drugs (this company)
₹455.8021.76₹4,247 Cr2.690.43%13.40%12.00%₹2,678 Cr₹191 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.51%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

58 Good

Data confidence 100/100

Category scores

Quality
64
Good
Returns, margins, earnings quality 22% weight
Valuation
76
Strong
Cheap vs sector & own history 24% weight
Growth
39
Weak
Sales & profit trajectory 9% weight
Financial Health
42
Weak
Solvency, leverage, coverage 9% weight
Momentum
55
Good
Trend strength, vol-adjusted 12% weight
Ownership
54
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

5
  • Promoter holding has decreased over last quarter: -0.36%
  • The company has delivered a poor sales growth of 3.55% over past five years.
  • Company has a low return on equity of 13.3% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 6.72% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2413
OscillatorsBullish243
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
62.55
Neutral
MACD (12,26,9)
9.05
Bullish
SMA (50)
421.33
Bullish
SMA (200)
390.04
Bullish

As of

Analyst Rating

Based on 1 analysts
HOLD100%

0 of 1 analyst rates Buy, 1 Hold, 0 Sell.

As of

BUY
0
0%
HOLD
1
100%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+8.45%
5Y+3.54%
3Y−1.89%
1Y+7.46%
TTM+10.52%

Net profit

Net profit growth by window
10Y+10.95%
5Y−6.98%
3Y+5.51%
1Y+16.07%
TTM+1.06%

Operating cash flow

Operating cash flow growth by window
10Y+6.68%
5Y+10.38%
3Y+24.07%
1Y+3.67%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−3.63 pp
5Y−8.26 pp
3Y+0.78 pp
1Y+0.01 pp
TTM+0.21 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,195 Cr
Mar 2018₹1,244 Cr
Mar 2019₹1,561 Cr
Mar 2020₹1,806 Cr
Mar 2021₹2,155 Cr
Mar 2022₹2,489 Cr
Mar 2023₹2,716 Cr
Mar 2024₹2,529 Cr
Mar 2025₹2,387 Cr
Mar 2026₹2,565 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹82.00 Cr
Mar 2018₹82.00 Cr
Mar 2019₹90.00 Cr
Mar 2020₹141 Cr
Mar 2021₹280 Cr
Mar 2022₹205 Cr
Mar 2023₹166 Cr
Mar 2024₹172 Cr
Mar 2025₹168 Cr
Mar 2026₹195 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹404 Cr +29.5% vs FY26
Reported High Mean Low

Quarterly Results

₹ Cr
AARTIDRUGS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
661
642
606
620
555
598
557
677
591
653
602
720
703
826
Expenses
577
565
536
534
490
531
495
583
516
569
547
624
605
691
Operating Profit
84
76
70
86
65
67
62
93
74
84
55
96
98
135
OPM %
13%
12%
12%
14%
12%
11%
11%
14%
13%
13%
9%
13%
14%
16%
Other Income
1
1
2
1
1
1
12
2
0
0
1
1
−1
3
Interest
9
8
8
9
9
9
9
9
9
8
9
8
9
10
Depreciation
13
13
13
14
13
14
14
15
15
16
18
18
18
19
PBT
64
56
52
64
44
46
51
71
51
60
29
70
69
109
Tax %
24%
30%
29%
26%
24%
24%
27%
12%
−6%
25%
−40%
21%
28%
24%
Net Profit
48
40
37
47
33
35
37
63
54
45
41
55
50
83
EPS (₹)
5.17
4.31
3.99
5.15
3.62
3.84
4.06
6.89
5.91
4.96
4.44
6.05
5.5
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
AARTIDRUGS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,097
1,140
1,195
1,244
1,561
1,806
2,155
2,489
2,716
2,529
2,387
2,565
2,678
Expenses
925
960
1,005
1,042
1,350
1,541
1,714
2,156
2,407
2,208
2,097
2,254
2,344
Operating Profit
172
180
190
202
211
266
440
333
309
321
290
312
333
OPM %
16%
16%
16%
16%
14%
15%
20%
13%
11%
13%
12%
12%
12%
Other Income
1
0
4
1
6
6
5
11
2
4
16
2
1
Interest
42
48
40
38
44
37
26
24
37
38
39
36
34
Depreciation
31
37
38
40
43
49
50
50
50
51
56
67
71
PBT
100
95
116
125
131
185
369
270
224
236
212
211
229
Tax %
23%
28%
29%
34%
32%
24%
24%
24%
26%
27%
21%
8%
—
Net Profit
77
69
82
82
90
141
280
205
166
172
168
195
191
EPS (₹)
7.97
7.09
8.57
8.73
9.52
15.17
30.09
22.14
17.96
18.65
18.42
21.36
20.95
Div. Payout %
41%
24%
3%
3%
3%
3%
8%
5%
6%
5%
5%
9%
—

Balance Sheet

₹ Cr
AARTIDRUGS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
24
24
24
24
24
23
93
93
93
92
91
91
Reserves
284
333
376
432
520
629
820
944
1,100
1,190
1,278
1,458
Borrowings
448
483
480
546
507
389
351
543
609
564
615
577
Other Liabilities
248
261
311
388
405
535
502
629
620
587
591
690
Total Liabilities
1,004
1,102
1,191
1,389
1,455
1,576
1,766
2,208
2,421
2,432
2,575
2,815
Fixed Assets
448
493
581
602
625
644
665
690
676
811
866
1,086
CWIP
16
34
14
28
33
12
19
77
210
261
330
214
Investments
5
5
12
11
12
13
17
19
19
20
22
27
Other Assets
534
570
584
748
785
907
1,064
1,422
1,516
1,340
1,356
1,488
Total Assets
1,004
1,102
1,191
1,389
1,455
1,576
1,766
2,208
2,421
2,432
2,575
2,815

Cash Flow

₹ Cr
AARTIDRUGS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
105
133
175
70
143
251
155
70
133
359
245
254
Investing
−107
−99
−107
−74
−62
−33
−72
−150
−164
−224
−165
−173
Financing
1
−33
−68
4
−80
−215
−81
92
17
−136
−82
−77
Net Cash Flow
−1
1
0
0
1
2
2
13
−14
−1
−2
3
Free Cash Flow
−2
34
68
−5
80
214
78
−82
−31
133
67
80
CFO/EBITDA
69
85
103
47
82
110
57
46
62
131
103
80

Ratios

AARTIDRUGS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
105
106
91
110
107
99
94
110
116
102
115
118
Inventory Days
82
86
100
132
86
102
117
115
101
107
114
112
Days Payable
83
90
94
123
85
104
93
103
94
94
100
109
Cash Conversion Cycle
104
103
97
119
109
97
118
123
123
115
129
121
Working Capital Days
14
19
22
33
44
54
77
63
72
74
76
76
ROCE %
—
18%
18%
17%
17%
21%
34%
21%
15%
15%
13%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aarti Drugs insights

67 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 54.07%
  • Public 23.86%
  • DIIs 10.24%
  • Others 9.57%
  • FIIs 2.26%

2.51% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Aarti Drugs

What does Aarti Drugs Ltd do?
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations.
Where is Aarti Drugs Ltd (AARTIDRUGS) listed?
Aarti Drugs Ltd trades as AARTIDRUGS on the NSE and under code 524348 on the BSE.
Which sector does Aarti Drugs Ltd belong to?
Aarti Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Aarti Drugs Ltd?
Aarti Drugs Ltd trades at a PE ratio of 21.76 as of 4 Nov 2026, on earnings per share of ₹20.95, against a book value of ₹169.7 per share.
What is the 52-week high and low of Aarti Drugs Ltd?
Over the last 52 weeks Aarti Drugs Ltd has traded between ₹318.95 and ₹534 as of 4 Nov 2026.
Does Aarti Drugs Ltd pay dividends?
Aarti Drugs Ltd has a dividend yield of 0.43%.
What is the Return on Equity (ROE) of Aarti Drugs Ltd?
Aarti Drugs Ltd reported a return on equity of 13.40%. Its debt-to-equity ratio is 0.37.

Company Information

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. It is exporting its API's and Speciality chemicals to over 100 countries across the globe.

Website aartidrugs.com
CEO Mr. Prakash Moreshwar Patil
Employees 1,284
Listed 19 Sep 2003
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AARTIDRUGS.md for Aarti Drugs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month